Соединенные Штаты - английский - NLM (National Library of Medicine)

new sun inc. - amyl nitrite (unii: 22t8z09xak) (amyl nitrite - unii:22t8z09xak), oyster shell calcium carbonate, crude (unii: 2e32821g6i) (oyster shell calcium carbonate, crude - unii:2e32821g6i), caulophyllum thalictroides root (unii: jtj6hh6yeh) (caulophyllum thalictroides root - unii:jtj6hh6yeh), black cohosh (unii: k73e24s6x9) (black cohosh - unii:k73e24s6x9), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), gelsemium sempervirens root (unii: 639kr60q1q) (gelsemium sempervirens root - unii:639kr60q1q), lachesis - indications: for temporary relief of discomforts associated with menopause: •hot flashes •sweats •chills/clammy skin •heat in the head •headaches •hot feet •mood swings •anxiety/sensitivity •wanting to be alone indications: for temporary relief of discomforts associated with menopause: - hot flashes - sweats - chills/clammy skin - heat in the head - headaches - hot feet - mood swings - anxiety/sensitivity - wanting to be alone

Соединенные Штаты - английский - NLM (National Library of Medicine)

king bio inc. - equal volumes of each hpus ingredient in 10x, 30x, and 1lm potencies., amyl nitrosum, calcarea carbonica, caulophyllum thalictroides, cimicifuga racemosa, ferrum metallicum, gelsemium sempervirens, lachesis mutus, pulsatilla, sanguinaria canadensis, sepia, sulphur, sulphuricum acidum., reference image: menopause.jpg - for temporary relief of of discomforts associated with menopause:  hot flashes  night sweats  chills  headaches uterine cramps  mood swings  sensitivity  irritability fatigue  poor memory as per various homeopathic materia medicas. claims based on traditional homeopathic practice, not accepted medical evidence. these uses have not been evaluated by the fda, and product has not been clinically tested. reference image: menopause.jpg equal volumes of each hpus ingredient in 10x, 30x, and 1lm potencies. amyl nitrosum................................hot flashes, profuse sweating calcarea carbonica ....................headaches, night sweats, chills caulophyllum thalictroides .........................irritability, exhaustion cimicifuga racemosa........................................... uterine cramps ferrum metallicum ........................................................irritability gelsemium sempervirens ....................... inability to concentrate lachesis mutus ............................prefer

Канада - английский - Health Canada

allen & hanburys a glaxo canada ltd. co. - amyl nitrite - liquid - .3ml - amyl nitrite .3ml - nitrates and nitrites

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - dichlorobenzyl alcohol; amylmetacresol - lozenge - 1.2mg ; 600microgram

Израиль - английский - Ministry of Health

reckitt benckiser (near east) ltd - amylmetacresol; dichlorobenzyl alcohol - lozenges - dichlorobenzyl alcohol 1.2 mg; amylmetacresol 0.6 mg - dichlorobenzyl alcohol - dichlorobenzyl alcohol - antiseptic for the relief of sore throat in children and adults.

Филиппины - английский - FDA (Food And Drug Administration)

actimed, inc - dichlorobenzyl alcohol , amylmetacresol - lozenge - 1.2mg/ 600mcg

Канада - английский - Health Canada

knoll pharma inc. - amylmetacresol - lozenge - 0.6mg - amylmetacresol 0.6mg - miscellaneous anti-infectives

Бельгия - английский - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

geiser pharma s.l. - amylmetacresol 0,6 mg; dichlorobenzyl alcohol 1,2 mg - lozenge - 1,2 mg - 0,6 mg - amylmetacresol 0.6 mg; dichlorobenzyl alcohol 1.2 mg - various

Мальта - английский - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - amylmetacresol - lozenge - amylmetacresol 0.6 mg - throat preparations

Соединенные Штаты - английский - NLM (National Library of Medicine)

vivus llc - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50) - pancreaze is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. none. risk summary published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of pancrelipase in either human or animal milk, the effects on the breastfed infant or the effects on milk production. pancrelipase is minimally absorbed systemically following oral administration, therefore maternal use is not expected to result in clinically relevant exposure of breastfed infants to the drug. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for pancreaze and any potential adverse effects on the breastfed infant from pancreaze or from the underlying maternal condition. the safety and effectiveness of pancreaze for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients. use of pancreaze for this indication is supported by an adequate and well-controlled trial in adult and pediatric patients 8 to 17 years of age (study 1) along with supportive data from a randomized, investigator-blinded, dose-ranging study in 17 pediatric patients aged 6 to 30 months (study 2). both study populations consisted of patients with exocrine pancreatic insufficiency due to cystic fibrosis. the safety in pediatric patients in these studies was similar to that observed in adult patients [see adverse reactions (6.1) and clinical studies (14)] . dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. if there is a history of fibrosing colonopathy, monitor patients during treatment with pancreaze because some patients may be at risk of progressing to stricture formation. do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation . [see dosage and administration (2.2)and warnings and precautions (5.1)] . crushing or chewing pancreaze capsules or mixing the capsule contents in foods having a ph greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see dosage and administration (2.3)and warnings and precautions (5.2)]. clinical studies of pancreaze did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. other reported clinical experience has not identified differences in responses between patients aged 65 years and over and younger adult patients.